159 related articles for article (PubMed ID: 19491258)
1. Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.
Ports MO; Nagle RB; Pond GD; Cress AE
Cancer Res; 2009 Jun; 69(12):5007-14. PubMed ID: 19491258
[TBL] [Abstract][Full Text] [Related]
2. Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.
Demetriou MC; Pennington ME; Nagle RB; Cress AE
Exp Cell Res; 2004 Apr; 294(2):550-8. PubMed ID: 15023541
[TBL] [Abstract][Full Text] [Related]
3. The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model.
King TE; Pawar SC; Majuta L; Sroka IC; Wynn D; Demetriou MC; Nagle RB; Porreca F; Cress AE
PLoS One; 2008; 3(10):e3535. PubMed ID: 18958175
[TBL] [Abstract][Full Text] [Related]
4. Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model.
Landowski TH; Gard J; Pond E; Pond GD; Nagle RB; Geffre CP; Cress AE
Mol Cancer Ther; 2014 Jun; 13(6):1558-66. PubMed ID: 24739392
[TBL] [Abstract][Full Text] [Related]
5. Integrin alpha6 cleavage: a novel modification to modulate cell migration.
Pawar SC; Demetriou MC; Nagle RB; Bowden GT; Cress AE
Exp Cell Res; 2007 Apr; 313(6):1080-9. PubMed ID: 17303120
[TBL] [Abstract][Full Text] [Related]
6. Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer.
Sroka IC; Sandoval CP; Chopra H; Gard JM; Pawar SC; Cress AE
Mol Cancer Res; 2011 Oct; 9(10):1319-28. PubMed ID: 21824975
[TBL] [Abstract][Full Text] [Related]
7. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor.
Fritz V; Noël D; Bouquet C; Opolon P; Voide R; Apparailly F; Louis-Plence P; Bouffi C; Drissi H; Xie C; Perricaudet M; Müller R; Schwarz E; Jorgensen C
Stem Cells; 2008 Nov; 26(11):2981-90. PubMed ID: 18757301
[TBL] [Abstract][Full Text] [Related]
8. Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell-Cell Biophysical Properties in Prostate Cancer.
Rubenstein CS; Gard JMC; Wang M; McGrath JE; Ingabire N; Hinton JP; Marr KD; Simpson SJ; Nagle RB; Miranti CK; Warfel NA; Garcia JGN; Arif-Tiwari H; Cress AE
Cancer Res; 2019 Sep; 79(18):4703-4714. PubMed ID: 31337652
[TBL] [Abstract][Full Text] [Related]
9. Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.
Kacsinta AD; Rubenstein CS; Sroka IC; Pawar S; Gard JM; Nagle RB; Cress AE
Biochem Biophys Res Commun; 2014 Nov; 454(2):335-40. PubMed ID: 25450398
[TBL] [Abstract][Full Text] [Related]
10. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
11. Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
Wilson MJ; Sinha AA
Anat Rec; 1997 Sep; 249(1):63-73. PubMed ID: 9294650
[TBL] [Abstract][Full Text] [Related]
12. Integrin clipping: a novel adhesion switch?
Demetriou MC; Cress AE
J Cell Biochem; 2004 Jan; 91(1):26-35. PubMed ID: 14689578
[TBL] [Abstract][Full Text] [Related]
13. alpha6 integrin cleavage: sensitizing human prostate cancer to ionizing radiation.
Pawar SC; Dougherty S; Pennington ME; Demetriou MC; Stea BD; Dorr RT; Cress AE
Int J Radiat Biol; 2007; 83(11-12):761-7. PubMed ID: 18058365
[TBL] [Abstract][Full Text] [Related]
14. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases.
Koutsilieris M; Frenette G; Lazure C; Lehoux JG; Govindan MV; Polychronakos C
Anticancer Res; 1993; 13(2):481-6. PubMed ID: 7685989
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components.
Xue W; Mizukami I; Todd RF; Petty HR
Cancer Res; 1997 May; 57(9):1682-9. PubMed ID: 9135008
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression.
Ricci E; Mattei E; Dumontet C; Eaton CL; Hamdy F; van der Pluije G; Cecchini M; Thalmann G; Clezardin P; Colombel M
Prostate; 2013 Dec; 73(16):1738-46. PubMed ID: 24115186
[TBL] [Abstract][Full Text] [Related]
17. Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo.
Rabinovitz I; Nagle RB; Cress AE
Clin Exp Metastasis; 1995 Nov; 13(6):481-91. PubMed ID: 7586806
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
19. Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer.
Banyard J; Chung I; Migliozzi M; Phan DT; Wilson AM; Zetter BR; Bielenberg DR
BMC Cancer; 2014 May; 14():387. PubMed ID: 24885350
[TBL] [Abstract][Full Text] [Related]
20. Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies.
Hart CA; Scott LJ; Bagley S; Bryden AA; Clarke NW; Lang SH
Br J Cancer; 2002 Apr; 86(7):1136-42. PubMed ID: 11953862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
